Since receiving IRB approval in 2024, we are now enrolling research volunteers in order to measure, quantify, and elucidate the full spectrum of antibodies each patient creates to battle their own disease.

Once the research is complete, we will go to the FDA with our treatment plan, seek approval, and then begin designing a clinical trial to test the efficacy of our treatment method that leverages all the unique antibodies in each patient.

Provided all goes according to plan, the hope is to scale up the clinical trials and share these successful results with the research community, so all patients may benefit.